Myriad Genetics Expands Strategic Research Collaboration With AbbVie

Myriad Genetics, Inc. (NASDAQ:MYGN) announced an expanded companion diagnostics (CDx) research collaboration with AbbVie, Inc. to support the development of AbbVie’s investigational PARP inhibitor, veliparib.
According to the company:

Under the terms of the agreement, AbbVie will use Myriad’s CDx portfolio – myChoice HRD™ and new tumor tests – to help identify patients with non-small cell lung cancer who are likely to respond to treatment with the combination of veliparib and chemotherapy. Other terms of the deal were not disclosed.

Jerry Lanchbury, chief scientific officer, Myriad Genetics commented:

As a company committed to innovation in the field of oncology, this collaboration with AbbVie enables us to use our proprietary companion diagnostics to advance care for patients with lung cancer. If we are successful, our companion diagnostics will identify more patients who may benefit from treatment with the combination of veliparib and chemotherapy.

Click here to view the full press release.